Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Overview
Date Founded

2011

Headquarters

60 LEVERONI COURT, NOVATO, CA, 94949

Type of Company

Public

Employees (Worldwide)

610

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Contact Data
Trying to get in touch with decision makers at Ultragenyx Pharmaceutical, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President & Chief Executive Officer

Chief Operating Officer

General Counsel & Executive Vice President

Executive Vice President & Chief Commercial Officer

Chief Business Officer & Executive Vice President

Vice President, Corporate Controller & Principal Accounting Officer

Chief Medical Officer & Executive Vice President

Chief Technical Operations Officer & Executive Vice President

Chief Quality Operations Officer & Executive Vice President, Translational Sciences

Senior Vice President-Global Clinical Development

Board of Directors

Professional at Intercept Pharmaceuticals, Inc.

Co-Founder at Seattle Genetics, Inc.

President & Chief Executive Officer at H. Lundbeck A/S

Senior Advisor, Finance at Crinetics Pharmaceuticals, Inc.

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Co-Chair, Executive Women in Bio Program at Women in Bio, Inc.

Founder, President & Chief Executive Officer at Ultragenyx Pharmaceutical, Inc.

Professional at Applied Genetic Technologies Corp.

President, Chief Executive Officer & Director at Coda Biotherapeutics, Inc.

Paths to Ultragenyx Pharmaceutical, Inc.
Potential Connections via
Relationship Science
You
Ultragenyx Pharmaceutical, Inc.
Owners & Shareholders
Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm is a multi strategy investor that manages portfolios of equity and fixed-income investments for institutional and private clients. Their strategies include core international/emerging market equities; international equity; international small- and mid-cap equity; balanced/asset allocation; managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Details Hidden

Alkeon Capital Management invests principally, but not solely, in long or short positions of publicly-traded and private companies in global markets on behalf of the funds it manages. They provides advisory or sub-advisory services to its clients using the general strategy except that (a) the Alkeon Growth Funds, the OAM Funds, ALPRO Growth, MS UCITs and the Insurance Series primarily invest in long and short positions of global growth stocks; (b) the Alkeon Select Funds and the Alkeon Capital Partners Fund invest primarily in long positions of global growth stocks; and (c) the Alkeon Asia Growth Funds invest primarily in long and short positions of global growth stocks based in the Asia Pacific region. Alkeon Capital Management employs a bottom-up, fundamentally driven, research-intensive approach to investing. On the long side, their investment program focuses on investing in the equity securities of companies that Alkeon believes are well positioned to benefit from demand for their products or services, including companies that can innovate or grow rapidly relative to their peers in their markets. On the short side, Alkeon Capital Management may affect short sales of securities when it believes that the market price of a security is above its estimated intrinsic or fundamental value. This analytical process involves the use of valuation models, review and analysis of published research, and, in some cases, discussions with industry experts and company visits. Alkeon also takes into account economic and market conditions.

Details Hidden

CWAM provides professional management of global equity assets using in-house resources to seek superior long term results. The firm follows a fundamental, research-intensive investment style characterized by unconventional stock picking and multi-year time horizon.CWAM's investment style can be best described as growth at a reasonable price (GARP). The firm seeks to buy growing, undervalued companies, grow with them, and sell them when their growth slows or when they believe they are fully valued. The firm is particularly interested in underfollowed stocks and niche companies. They like companies that benefit from long-term trends that CWAM identifies. The firm uses dividend discount, private market value and cash flow models to value stocks. CWAM especially likes companies with hidden values beyond reported EPS, such as unusually high free cash flow, masked earnings power or hidden assets. They usually avoid companies in highly competitive or unpredictable industries, such as airlines, commodity semiconductors and many natural resource areas. CWAM invests client assets in certain small to medium capitalization companies, both US and foreign, that it believes have growth potential, financial strength and fundamental value. Although the firm invests its managed assets primarily in equity securities, it may also invest in other types of securities.

Recent Transactions
Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. purchases Dimension Therapeutics, Inc.

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Escrow Agent

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Co-Chairman, Life Sciences Practice Group

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Professional

Advised onUltragenyx Pharmaceutical, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Fenwick & West LLP

Clients

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$3.68B
Total Enterprise Value
$1.7B
Earnings Per Share
$-3.97
Revenue
$51.5M
Net Profit
$-198M
EBITDA
$-352M
EBITDAMargin
-683.24%
Total Debt
$0
Total Equity
$609M
Enterprise Value Sales
33.1x
TEVNet Income
-8.62x
Debt TEV
0x
Investors
Details Hidden

TPG Biotech is a life science venture capital platform of TPG Capital. TPG Biotech focuses on therapeutics, medical devices, and healthcare services. By leveraging TPG''s global network to support portfolio companies, TPG Biotech provides access to opportunities and operational experts from other platforms. They target investments globally with a particular focus on opportunities in North America & Asia Pacific, and provides financing for early & later stage capital requirements.

Details Hidden

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Details Hidden

Pappas Ventures invests exclusively in the life sciences sector including biotechnology, specialty pharmaceuticals, diagnostics, drug delivery, medical devices and and other related ventures. They typically pursue early- to mid-stage investments. The firm places emphasis on companies with products or technologies at the pre-clinical, Phase 1 or Phase 2 stage of development. They invest across the spectrum of start-up companies to well-established companies.Pappas Ventures focuses on the quality and experience of a potential portfolio company's management team. They look for management teams with a proven track record, the ability to communicate the company's story to a variety of audiences and a deep commitment to creating shareholder value. The firm also seeks companies with a strong proprietary position, a large clearly-defined market and a realistic exit strategy.About one-third of their investments are made in California and about one-third are made in companies on the East Coast of the US including the Research Triangle area of North Carolina. The remaining capital is invested in underserved regions such as Texas, Indiana and Montreal.The firm invest anywhere from a seed deal to a later-stage mezzanine transaction.

Suppliers
Kyowa Hakko Kirin Co., Ltd. Chemicals | Tokyo, TY

Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, OS

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

IOI Corp. Bhd. Chemicals | Putrajaya, WP

IOI Group's formation years were associated with real estate when it forayed into property development in 1982 followed by Oil Palm plantations in 1985. Today, IOI Group is internationally known as a leading global integrated palm oil player with operations stretching the entire palm value chain from seedlings to plantations to crop oil extraction to diverse value-added manufacturing across major continents - serving global markets in more than 65 countries. Close to its home-base in Malaysia, the Group is also prominently known as one of the leading property developer with significant investment holdings of prime real-estates. IOI Group employs more than 30,000 personnel of more than 23 different nationalities in 15 countries.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ultragenyx Pharmaceutical, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ultragenyx Pharmaceutical, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ultragenyx Pharmaceutical, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/ultragenyx-pharmaceutical-inc-236522
  • https://relationshipscience.com/organization/ultragenyx-pharmaceutical-inc-236522